Stocks and Investing
Stocks and Investing
Thu, February 8, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
David Lebowitz Maintained (ASND) at Strong Buy with Increased Target to $182 on, Feb 8th, 2024
David Lebowitz of Citigroup, Maintained "Ascendis Pharma A/S" (ASND) at Strong Buy with Increased Target from $146 to $182 on, Feb 8th, 2024.
David has made no other calls on ASND in the last 4 months.
There are 4 other peers that have a rating on ASND. Out of the 4 peers that are also analyzing ASND, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $116 on, Thursday, November 9th, 2023
These are the ratings of the 3 analyists that currently disagree with David
- Li Watsek of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $173 on, Tuesday, February 6th, 2024
- Kelly Shi of "Jefferies" Initiated at Strong Buy and Held Target at $150 on, Wednesday, December 20th, 2023
- Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $149 on, Tuesday, December 19th, 2023
Contributing Sources